Skip to content
Research Article Open access CC BY 4.0

Biochemical and Serological Tests for People Recovering from COVID-19

Enass Waad Al-Hadidi, Mahmoud Abduljabbar Al-Tobji

South Asian Journal of Research in Microbiology · pp. 1–11 · Published 31 Aug 2022

10.9734/sajrm/2022/v13i330298

Abstract

Aims: The purpose of this study was to detect some biological and serological factors in COVID-19 recovery patients, as well as their relationships with antibody levels 8 months after infection. Materials and Methods: 92 blood samples were obtained; 67 of them had COVID-19 infections 4 months prior, and 25 blood samples served as control samples. The participants' ages ranged from 17-75 year. Determination levels of immunoglobulin IgG and IgM antibodies was carried out on (188) samples of infection over for ages ranging from 15-75 years by using enzyme linked immunosorbant assay  (ELISA). Results: The people under research have 94.03% IgG and 55.22% IgM. Furthermore, the maximum concentration of IgG was seen after 6 months of infection. Aberrant lactate dehydrogenase (LDH) levels were found in 20 people at 41.6% after 4 months, in 25 people at 52.08% after 6 months, and in 8 people at 8.33% after 8 months. In contrast, aberrant C- reactive protein (CRP) levels were found in 10.4% of the participants after 4 to 8 months of infection and 12.5% after 6 months, with no significant association between them. Conclusion: The maximum IgG level was reported 6 months after infection, and the LDH and CRP tests were abnormal 6 months later. On the other hand, 4 months after the infection, both urea and creatinine levels were abnormal, as was the IgG concentration.

COVID-19 IgG IgM LDH ELISA SARS-CoV-2

References (31)

  1. 1 Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [DOI]
  2. 2 Clinical Characteristics of Coronavirus Disease 2019 in China [DOI]
  3. 3 Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study [DOI]
  4. 4 Home visits: a strategy to improve newborn survival - Authors' reply [DOI]
  5. 5 Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study [DOI]
  6. 6 Correspondence - Tranexamic acid for traumatic brain injury [DOI]
  7. 7 The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 [DOI]
  8. 8 Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor [DOI]
  9. 9 Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia [DOI]
  10. 10 Rapid spread of the SARS-CoV-2 Delta variant in some French regions, June 2021 [DOI]
  11. 11 Prevalence of Underlying Diseases in Hospitalized Patients with COVID-19: a Systematic Review and Meta-Analysis. [DOI]
  12. 12 Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts [DOI]
  13. 13 The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management [DOI]
  14. 14 Evaluation of Nucleocapsid and Spike Protein-Based Enzyme-Linked Immunosorbent Assays for Detecting Antibodies against SARS-CoV-2 [DOI]
  15. 15 The ORF8 protein of SARS-CoV-2 mediates immune evasion through down-regulating MHC-Ι [DOI]
  16. 16 Detection of IgM and IgG antibodies in patients with coronavirus disease 2019 [DOI]
  17. 17 Detectable 2019-nCoV viral RNA in blood is a strong indicator for the further clinical severity [DOI]
  18. 18 The influence of age, sex, and race on the upper reference limit of serum C-reactive protein concentration.
  19. 19 The Physiology of Urinary Concentration: An Update [DOI]
  20. 20 A Peptide-Based Magnetic Chemiluminescence Enzyme Immunoassay for Serological Diagnosis of Coronavirus Disease 2019 [DOI]
  21. 21 Differences in Antibody Kinetics and Functionality Between Severe and Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infections [DOI]
  22. 22 Community-acquired and hospital-acquired respiratory tract infection and bloodstream infection in patients hospitalized with COVID-19 pneumonia [DOI]
  23. 23 Meta-analysis of diagnostic performance of serological tests for SARS-CoV-2 antibodies up to 25 April 2020 and public health implications [DOI]
  24. 24 B cell analysis in SARS-CoV-2 versus malaria: Increased frequencies of plasmablasts and atypical memory B cells in COVID-19 [DOI]
  25. 25 Acute Kidney Injury in Patients with the Coronavirus Disease 2019: A Multicenter Study [DOI]
  26. 26 D-dimer, Troponin, and Urea Level at Presentation With COVID-19 can Predict ICU Admission: A Single Centered Study [DOI]
  27. 27 Comparing Immunoassays for SARS-CoV-2 Antibody Detection in Patients with and without Laboratory-Confirmed SARS-CoV-2 Infection [DOI]
  28. 28 Longitudinal Profiling of Antibody Response in Patients With COVID-19 in a Tertiary Care Hospital in Beijing, China [DOI]
  29. 29 Controlled Release of Protein from Viable Lactococcus lactis Cells [DOI]
  30. 30 Concentrations of CTX I, CTX II, DPD, and PYD in the urine as a biomarker for the diagnosis of temporomandibular joint osteoarthritis: A preliminary study [DOI]
  31. 31 Temporal Associations of the SARS-CoV-2 NP Antigen and Anti-Spike Total Ig Levels with Laboratory Parameters in a Greek Cohort of Hospitalized COVID-19 Patients [DOI]

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

28

Page views

0

PDF downloads

4

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.